HoldsUp

Steven Bartlett

Steven Bartlett is the host or producer of a podcast series featuring interviews with researchers and medical experts. The discussions cover scientific topics such as parental neuroscience, human performance, vitamin supplementation, and cancer research. There are no academic publications listed in the provided records.

11 claims checked on air: 5 overstated 6 supported

What they said on air

0:29:40supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Low-income countries like Niger, Gambia, and Nepal have among the lowest recorded cancer incidence rates globally, while high-income countries like Australia, New Zealand, and the United States have the highest.

"When we look at the populations around the world that have the most prevalence of cancer, it doesn't appear to be some of the countries like Niger, Gambia, Nepal consistently rank at the very bottom for cancer incidence. Conversely, high-income countries like Australia, New Zealand, and the United States have the highest rates of cancer." (said at 0:29:40)

Global cancer statistics compiled by the International Agency for Research on Cancer (IARC/WHO GLOBOCAN) confirm that high-income countries and regions (notably Australia, New Zealand, and North America/United States) report the highest age-standardized cancer incidence rates globally, whereas low-income regions in Western Africa (including Niger and Gambia) and South-Central Asia (including Nepal) report among the lowest recorded incidence rates. The data also indicate that recorded incidence correlates strongly and positively with national income (GNI) and the Human Development Index (HDI), though underdiagnosis and registry coverage limitations in low-income settings contribute to the recorded disparity.

1:00:22overstatedlowLeading Cancer Researcher: They’re Ignoring My Research

Being in a state of ketosis can act as an adjuvant therapy that enhances the tumor-killing efficacy of chemotherapy while protecting healthy cells.

"The current body of research suggests that being in a state of ketosis can act as a helper therapy enhancing the cancer killing effects of chemotherapy while simultaneously protecting healthy cells." (said at 1:00:22)

While preclinical models and theoretical mechanisms (such as differential metabolic and oxidative stress) suggest that ketosis or ketogenic diets may sensitize cancer cells to chemotherapy while protecting normal tissues, human clinical evidence remains preliminary and inconclusive. Systematic reviews and meta-analyses of randomized trials indicate that evidence for enhanced tumor-killing efficacy and improved clinical survival in humans is currently insufficient, although the diet appears generally tolerable and may help alleviate certain side effects.

1:00:54supportedlowLeading Cancer Researcher: They’re Ignoring My Research

Entering a fasted ketogenic state causes normal healthy cells to slow division and bolster defenses, whereas cancer cells continue dividing rapidly, rendering them selectively vulnerable to chemotherapy damage.

"When you enter a fasted ketogenic state, your healthy cells essentially go into bunker mode. They slow their division, conserve energy, and build up their defenses. Cancer cells, however, do not have this evolutionary off switch. They continue trying to rapidly divide. When the toxic chemotherapy hits, your shielded healthy cells survive it it much better while the exposed rapidly dividing cancer cells take the full hit." (said at 1:00:54)

The host accurately describes the biological phenomenon known as 'differential stress resistance' (DSR) and 'differential stress sensitization' (DSS). In preclinical cell and animal models, nutrient deprivation and fasting cause normal cells to downregulate growth pathways (e.g., IGF-1, mTOR, PKA) and divert resources toward cellular maintenance and protection, while oncogene-driven cancer cells fail to arrest division and become selectively susceptible to chemotherapy toxicity and oxidative damage. While this mechanistic principle is well-established in vitro and in animal studies, clinical trial evidence confirming therapeutic efficacy and safety in human cancer patients remains preliminary.

1:02:23overstatedvery lowLeading Cancer Researcher: They’re Ignoring My Research

Chemotherapy generates oxidative stress and DNA damage in tumors requiring high levels of glucose for repair, meaning ketosis impedes DNA repair and accelerates tumor cell death.

"chemotherapy creates massive oxidative stress, i.e. damage inside the tumor. To repair the damage and survive, the cancer cell requires massive amounts of glucose. So, if the patient is in ketosis, the tumor's glucose supply is essentially cut off. It can't the cancer cell can't repair the DNA damage caused by your chemo leading to faster tumor death." (said at 1:02:23)

The statement accurately reflects a prominent biochemical hypothesis in cancer metabolism: that cancer cells rely heavily on glucose flux (notably via the pentose phosphate pathway to generate NADPH) to mitigate oxidative stress and repair damage caused by therapies such as chemotherapy and radiation. In vitro and rodent xenograft models show that glucose restriction via a ketogenic diet can augment oxidative stress and enhance sensitivity to chemo-radiotherapy. However, stating this as an established clinical fact overstates the evidence: human data remain limited to small phase 1 trials where compliance and tolerability were major limiting factors, and definitive clinical efficacy in accelerating tumor cell death in patients has not been demonstrated.

1:10:32supportedhighLeading Cancer Researcher: They’re Ignoring My Research

The American Cancer Society projects over 2.11 million new cancer diagnoses and approximately 626,000 cancer deaths in the United States in 2026.

"the ACS projects over 2.11 million new cancer diagnoses in 2026. This translates roughly to 5,800 new cases every single day. Approximately 626,000 Americans are expected to die from cancer in 2026." (said at 1:10:32)

According to the American Cancer Society's annual report 'Cancer statistics, 2026', approximately 2,114,850 new cancer cases (over 2.11 million) and 626,140 cancer deaths (approximately 626,000) are projected to occur in the United States in 2026.

1:11:08supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Lung cancer causes more deaths in the United States than colorectal and pancreatic cancers combined.

"Lung cancer remains the leading cause of cancer death projected to cause more fatalities than colorectal and pancreatic cancers combined." (said at 1:11:08)

Surveillance and vital statistics data compiled annually by the American Cancer Society and the National Center for Health Statistics confirm that lung cancer is the leading cause of cancer death in the United States and causes more deaths than the second- and third-leading causes (colorectal and pancreatic cancers) combined.

1:21:42overstatedlowLeading Cancer Researcher: They’re Ignoring My Research

Exposure to synthetic pesticides increases the risk of lymphoma by 41 percent.

"Synthetic pesticides. I was reading here that it in- increases the chance of lymphoma by a staggering 41%." (said at 1:21:42)

The 41% figure originates from a specific 2019 meta-analysis (Zhang et al.) examining occupational exposure to glyphosate-based herbicides (a specific herbicide, not all synthetic pesticides broadly) and the risk of non-Hodgkin lymphoma (NHL). Furthermore, that 41% increase (meta-RR = 1.41, 95% CI: 1.13–1.75) applied specifically to individuals in the highest cumulative exposure tier, rather than general or any pesticide exposure. Other meta-analyses of ever-exposure to glyphosate have reported lower, non-statistically significant associations (e.g., meta-RR 1.03–1.05).

1:24:23overstatedlowLeading Cancer Researcher: They’re Ignoring My Research

Fasting-mimicking diets significantly reduce IGF-1, trigger cellular autophagy, and enhance the efficacy of standard cancer therapies by up to threefold.

"Dr. Valter Longo's—who's Dr. His extensive research, clinical trials prove that fasting-mimicking diets drastically lower IGF-1, which triggers cellular autophagy and actually makes standard cancer therapies up to three times more effective by removing the metabolic shield of cancer cells." (said at 1:24:23)

Preclinical and early-phase clinical studies confirm that fasting-mimicking diets (FMD) reduce circulating IGF-1, inhibit growth pathways, and induce cellular stress/autophagy. Regarding efficacy, a phase 2 randomized trial of 131 HER2-negative breast cancer patients receiving neoadjuvant chemotherapy (the DIRECT trial) found an odds ratio of 3.168 for radiological response and 4.109 for pathological response (90-100% tumor cell loss) in per-protocol analysis. However, generalising an odds ratio from a preliminary phase 2 breast cancer study to an established claim that FMD triples the efficacy of standard cancer therapies broadly is an overstatement; larger phase 3 trials evaluating definitive survival outcomes across different tumor types are still ongoing.

1:26:50supportedvery lowLeading Cancer Researcher: They’re Ignoring My Research

A 2013 study showed that combining a ketogenic diet with hyperbaric oxygen therapy resulted in a synergistic decrease in tumor growth and significantly extended survival in systemic metastatic cancer mouse models.

"There was a study in 2013 that demonstrated that while a ketogenic diet alone significantly slowed tumor growth in systemic metastatic cancer mouse models, combining the diet with hyperbaric oxygen therapy elicited a profound synergistic decrease in tumor growth and drastically increased survival times." (said at 1:26:50)

A 2013 preclinical study by Poff et al. evaluated the combination of a ketogenic diet and hyperbaric oxygen therapy (HBOT) in a systemic metastatic cancer mouse model (VM-M3). The authors found that while HBOT alone did not affect cancer progression, combining the ketogenic diet with HBOT resulted in a significant reduction in tumor growth rate and a 77.9% increase in mean survival time compared to controls.

1:28:44overstatedhighLeading Cancer Researcher: They’re Ignoring My Research

In late 2023, the International Agency for Research on Cancer (IARC) reclassified forever chemicals (PFAS, including PFOA) as Group 1 human carcinogens.

"In late 2023, the International Agency for Research on Cancer officially upgraded these forever chemicals, which are used in nonstick pans and food packaging, to a grade one carcinogen in humans." (said at 1:28:44)

In November 2023, an IARC Working Group evaluated two specific PFAS compounds: perfluorooctanoic acid (PFOA) was classified as "carcinogenic to humans" (Group 1), while perfluorooctanesulfonic acid (PFOS) was classified as "possibly carcinogenic to humans" (Group 2B). The claim overstates the decision by stating that IARC classified "forever chemicals (PFAS)" as a whole into Group 1, whereas the Group 1 designation applied specifically to PFOA.

1:30:00supportedhighLeading Cancer Researcher: They’re Ignoring My Research

The International Agency for Research on Cancer (IARC) classifies arsenic and cadmium as Group 1 carcinogens.

"The IARC classifies arsenic and cadmium as group one carcinogens and they're frequently found in unfiltered public water infrastructure." (said at 1:30:00)

The International Agency for Research on Cancer (IARC) officially classifies both arsenic and cadmium (and their inorganic compounds) as Group 1 agents ('carcinogenic to humans'). Multiple peer-reviewed publications and toxicological reviews document this classification.

Fact-checked episodes

Publications

No PubMed publication profile has been built for this speaker yet.